Explorative analysis of the < 25th and > 75th percentile of UC and BC patients for IL-10, IL-12, IL-13, SCGFβ and VEGF revealed that the inflammatory profile was relatively consistent across patients within each group. This evidence concerns the gene IL10 and breast cancer.